# IsomAb

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/isomab

- Industry: Biotechnology
- Headquarters: Nottingham, UK
- Website: www.isomab.bio
- Total disclosed funding: $0.9M
- Latest round: Seed (Feb 20, 2024)
- Investors on record: 3

## About

Based in Nottingham, UK, and founded in 2022, IsomAb Ltd, a.k.a. IsomAb operates as a biotechnology company that focuses on developing isoform-specific disease-modifying antibody treatments for life-threatening diseases, with an initial focus on peripheral ischaemia. In February 2024, IsomAb Ltd. raised GBP 7.5 million in seed funding led by Broadview Ventures, with participation from SCVC, Mercia Ventures, and the Midlands Engine Investment Fund. As of February 2024, Jackie Turnbull is the CEO of the company.

The company’s product line includes ISM-001, an antibody therapeutic with a high affinity, neutralizing antibody that specifically binds VEGF165b. ISM-001 is helpful in the treatment of patients with type II diabetes mellitus disease.

The company plans to use its proceeds from February 2024 funding to progress the development of the lead compound ISM-001 towards human clinical trials.

## Funding rounds

- Seed, Feb 20, 2024, $0.9M — Foresight Group, Broadview Ventures, Mercia EIS Fund

## Investors

- Foresight Group (https://capitalatlas.ai/funds/foresight-group) — Seed
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Seed
- Mercia EIS Fund — Seed